List of Aklief drug patents
Aklief is owned by Galderma Labs Lp.
Aklief contains Trifarotene.
Aklief has a total of 5 drug patents out of which 0 drug patents have expired.
Aklief was authorised for market use on 04 October, 2019.
Aklief is available in cream;topical dosage forms.
Aklief can be used as treatment of acne vulgaris, method of activating rargamma receptor, topical treatment of acne vulgaris.
Drug patent challenges can be filed against Aklief from 2023-10-05.
The generics of Aklief are possible to be released after 30 May, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Oct, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470871 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(2 years from now) | |
| US8227507 | GALDERMA LABS LP | Ligands that modulate RAR receptors |
Dec, 2025
(2 years from now) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(10 years from now) | |
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 4, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 2023-10-05
Market Authorisation Date: 04 October, 2019
Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM;TOPICAL
AKLIEF family patents
8
United States
6
European Union
3
France
3
Mexico
3
Australia
3
Russia
3
Brazil
3
Korea, Republic of
3
China
3
Japan
3
Canada
2
South Africa
2
Spain
1
Israel
1
Denmark
1
Austria
1
Hong Kong
1
Slovenia
1
Lithuania
1
Hungary
1
Singapore
1
Argentina
1
Portugal
1
Cyprus
1
Netherlands
1
Poland
1
Chile
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic